Barclays lowered the firm’s price target on Fortrea (FTRE) to $11 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea price target lowered to $14 from $25 at Evercore ISI
- Fortrea Holdings Earnings Call Signals Steady Turnaround
- Fortrea upgraded to Buy from Hold at TD Cowen
- Fortrea: Strengthening Fundamentals, Cost Efficiencies, and Resilient Demand Underpin Buy Rating
- Fortrea Backs GE Healthcare’s New PET Tracer in Completed Phase 1 Study